⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025

Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara Nigel G. Maher Alison J. Potter Elizabeth C. Paver Jordan W. Conway Serigne Lo Andrew J. Colebatch Georgina V. Long James S. Wilmott Richard A. Scolyer

View at Publisher

Ask AI

Bookmark

Share

Key Points

Discovery identified key genomic markers in melanocytic tumors, resulting in a new test for malignancy.
The validation cohort demonstrated a significant correlation between genomic test results and tumor characteristics in melanomas.
This study utilized both clinical and pathological data to enhance diagnostic accuracy for primary melanocytic tumors.
The findings may enable improved treatment decisions and monitoring strategies for melanoma patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Analysis of melanoma and nevi characteristics in discovery and validation cohorts suggests diagnostic improvements.

Abstract

Clinical and pathological characteristics of melanomas and nevi in discovery and validation cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5ef https://doi.org/10.1158/1078-0432.30029159

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
2Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
3Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
4Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
5Table S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
6Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
7Table S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
8Table S10 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025